This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
SMARCC2 / SWI/SNF complex subunit SMARCC2 · Western blot design guide
Design a Western Blot for SMARCC2
Source-linked SMARCC2 Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-SMARCC2 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
SMARCC2 Western Blot Experimental Design Guide
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~132.9 kDa | |
| Gel | 8–10% (standard starting point) | |
| Positive control | Adrenal gland (IHC candidate; verify WB) +4 more | |
| Negative control | Suggested KO / knockdown lysate |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | Phosphorylated + Acetylated | |
| Caveat | Phosphorylation-state controls | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 3 isoform(s) |
Section 1
Source-Linked SMARCC2 Western Blot Protocol Options
The A06370 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | various cells (catalog A06370) |
| Gel % | 8–10% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Wet/tank transfer; optimize duration (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A06370 · 1:2000 (catalog A06370) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected SMARCC2 Western Blot Band Size?
SMARCC2 is predicted at 132.9 kDa; isoforms and modifications are annotated, but their effects on observed migration are not demonstrated here.
| Band near 132.9 kDa | Compatible with the predicted SMARCC2 mass; confirm its identity. |
| Several bands at different masses | Isoforms 1, 2, and 3 are possible contributors, but their migration is unknown. |
| Band enriched in nuclear extract | Consistent with SMARCC2's nuclear location. |
| Weak band in a cytosolic fraction | Consistent with SMARCC2's nuclear location. |
💡Expected SMARCC2 appearanceSMARCC2 has a predicted mass of 132.9 kDa, but no empirical band size is supplied; verify band identity with appropriate controls.
| Predicted SMARCC2 mass | 132.9 kDa is the sequence-based reference, not a measured band position. |
| Splice isoform 1 | Its apparent mass relative to the other isoforms is not supplied. |
| Splice isoform 2 | Its apparent mass relative to the other isoforms is not supplied. |
| Splice isoform 3 | Its apparent mass relative to the other isoforms is not supplied. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Poor recovery of nuclear SMARCC2. | Check nuclear extraction and a nuclear loading control. |
| Band higher than expected | Band identity or migration is unverified. | Compare with a molecular-weight marker and use peptide blocking or an independent antibody. |
| Band lower than expected | A splice isoform is possible, but its mass is unknown. | Verify identity with an independent antibody or isoform-specific evidence. |
| Multiple bands | SMARCC2 has three named isoforms, though distinct bands are not established. | Use peptide blocking or an independent antibody to identify specific bands. |
| Weak or no signal | Nuclear SMARCC2 may be underrepresented in the sample. | Test a nuclear extract and check nuclear protein recovery. |
| Fragments below expected size | Sample degradation is possible. | Prepare fresh lysate with protease inhibitors and verify band identity. |
Experiment evidence
Western blot images showing SMARCC2 band
A06370 · SMARCC2
A06370 · SMARCC2
A06370 · SMARCC2
A30530 · SMARCC2
A30530 · SMARCC2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for SMARCC2 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for SMARCC2 in Western blot, you can use adrenal gland tissue, which has high HPA expression.
Positive control: Adrenal gland (IHC candidate; verify WB)
Negative control: Suggested KO / knockdown lysate
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: No supplied tissue is undetected, so use siRNA knockdown or a KO line as the negative control.
HPA tissue expression evidence for SMARCC2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | glandular cells | High | Protein (IHC) | HPA → |
| Appendix | glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | respiratory epithelial cells | High | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Medium | Protein (IHC) | HPA → |
| Liver | cholangiocytes | Medium | Protein (IHC) | HPA → |
| Ovary | follicle cells | Medium | Protein (IHC) | HPA → |
| Skeletal muscle | myocytes | Medium | Protein (IHC) | HPA → |
| Smooth muscle | smooth muscle cells | Medium | Protein (IHC) | HPA → |
Section 3
Advanced SMARCC2 Western Blot Tips
Deeper troubleshooting and optimisation questions for SMARCC2, answered from its protein features.
What band size should I expect for SMARCC2?
Band shift · The predicted mass of canonical SMARCC2 is 132.9 kDa. No observed band size is supplied, so use this as a reference rather than an exact migration position.
Could SMARCC2 isoforms produce different bands?
Isoforms · UniProt lists isoforms 1, 2 and 3. Isoforms 2 and 3 replace Q at canonical position 550 with a longer sequence; isoform 2 lacks canonical residues 1075–1189, and isoform 3 lacks 1075–1167. Check whether the antibody epitope is retained in each isoform. These sequence differences could affect band position, but visible separation is not established.
Which phosphorylation sites matter when interpreting SMARCC2 bands?
PTM · UniProt annotates phosphoserine at canonical positions 283, 286, 302, 304, 306, 347, 387 and 813, plus phosphothreonine at 548. These coordinates use UniProt canonical numbering and may differ from antibody or paper numbering. Their presence alone does not establish a visible band shift.
UniProt lists N6-(ADP-ribosyl)lysine at canonical position 312 and N6-acetyllysine at 326. Check these sites against an antibody’s epitope when interpreting signal. The annotations alone do not show whether either modification changes migration or antibody binding.
UniProt lists N6-(ADP-ribosyl)lysine at canonical position 312 and N6-acetyllysine at 326. Check these sites against an antibody’s epitope when interpreting signal. The annotations alone do not show whether either modification changes migration or antibody binding.
Does this guide establish induction of SMARCC2?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
What transfer method to use for SMARCC2 Western blot?
Transfer · Plan transfer around the 132.9 kDa predicted canonical protein and verify recovery with a molecular-weight marker. The supplied features do not identify a specific membrane, transfer method or setting.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A06370 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should I quantify SMARCC2 across samples?
Quantitation · SMARCC2 is annotated as nuclear and as a component of SWI/SNF complexes. Compare equivalent sample preparations and quantify the same identified band across lanes. If multiple bands appear, check isoform coverage and antibody epitope before combining their signals.
How should I interpret unexpected SMARCC2 bands?
Interpretation · Compare them with the 132.9 kDa canonical prediction and the sequence changes in isoforms 2 and 3. UniProt also annotates phosphorylation, ADP-ribosylation and acetylation, but these features alone cannot identify an unexpected band or explain an apparent mass difference. Check whether the antibody epitope occurs in each isoform.
Boster reagents
SMARCC2 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-BAF170 SMARCC2 Antibody
Cat # A06370
Real WB data
Anti-SMRC2 SMARCC2 Antibody
Cat # A30530
Real WB data
Anti-BAF170 (M388) SMARCC2 Antibody
Cat # A06370-1
Three catalogued anti-SMARCC2 antibodies have WB images. Their captions show specific cell samples and dilutions, including nuclear extracts and whole cell lysates; these examples do not establish performance across every listed reactive species.
Which to pick: For rat reactivity or the shown K562, A549, C6, and 3T3-L1 whole cell lysates, consider A06370-1. A30530 shows COLO205 cells at 1:2000; A06370 shows nuclear extracts from various cells at 1:2000. All three have WB images.
Source: BosterBio SMARCC2 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q8TAQ2.
- Human Protein Atlas. SMARCC2 tissue expression.
- PMC11651576 — target-verified WB comparison
- PMC9684443 — target-verified WB comparison
- PMC10333084 — target-verified WB comparison